A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2019
At a glance
- Drugs Nivolumab (Primary) ; Varlilumab (Primary)
- Indications B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Lymphatoid granulomatosis
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 07 Feb 2018 Planned End Date changed from 30 Nov 2019 to 31 Dec 2019.
- 07 Feb 2018 Planned primary completion date changed from 30 Nov 2019 to 31 Dec 2019.